Optimal antithrombotic strategies after ACS: GEMINI-ACS-1 - ACC.17
What does the future hold for optimal antithrombotic strategies after ACS? G. Steg leads us through one of the key, late-breaking trials at ACC.17, calling it a “stepping stone” to an exciting future in antiplatelet therapy. Learn why as we examine current DAPT and search for an alternative that can be both effective and cause less bleeding. Can the family of low dose anticoagulation agents such as rivaroxaban be the answer? Hear about the “bottom line” out here…
This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).